Tracy Vuong
Family · Concord, CANPI 1841878246
Payments from drug & device makers
Across 231 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$936
- GSK$517
- AbbVie$482
- Lundbeck LLC$439
- Novo Nordisk$362
- Bayer$358
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,277100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 53 | $936 |
| GSK | 20 | $517 |
| AbbVie | 21 | $482 |
| Lundbeck LLC | 14 | $439 |
| Novo Nordisk | 16 | $362 |
| Bayer | 14 | $358 |
| AstraZeneca | 15 | $335 |
| Otsuka America Pharmaceutical, Inc. | 12 | $307 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $235 |
| Boehringer Ingelheim | 10 | $229 |
| Exact Sciences | 9 | $222 |
| Amgen | 6 | $170 |
| Johnson & Johnson | 6 | $139 |
| Merck | 4 | $114 |
| Astellas Pharma US Inc | 5 | $111 |
| Pfizer | 5 | $108 |
| Dexcom, Inc. | 2 | $74 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
How this compares
$5,277 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 98 | $96,559 |
| MounjaroTirzepatide | 91 | $92,970 |
| EliquisApixaban | 77 | $89,881 |
| FarxigaDapagliflozin Propanediol | 50 | $56,926 |
| JanuviaSitagliptin Phosphate | 35 | $42,873 |
| OzempicSemaglutide | 39 | $37,146 |
| XareltoRivaroxaban | 28 | $34,086 |
| TrulicityDulaglutide | 30 | $28,120 |
| MyrbetriqMirabegron | 25 | $22,570 |
| TradjentaLinagliptin | 22 | $22,460 |
| VascepaIcosapent Ethyl | 27 | $21,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $19,628 |
| VraylarCariprazine Hcl | 13 | $17,696 |
| GlyxambiEmpagliflozin/Linagliptin | 13 | $14,409 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $13,252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $229 | $133,428133 claims |
| Lilly USA, LLCMounjaro, Trulicity | $936 | $121,090121 claims |
| PfizerEliquis, Premarin | $108 | $95,22990 claims |
| AstraZenecaFarxiga | $335 | $56,92650 claims |
| MerckJanuvia | $114 | $42,87335 claims |
| Novo NordiskOzempic | $362 | $37,14639 claims |
| Johnson & JohnsonXarelto | $139 | $34,08628 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $517 | $32,88049 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $22,57025 claims |
| AbbVieVraylar, Synthroid | $482 | $19,40752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Concord
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.